Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease

• Published in: La Presse médicale (1983) Vol. 40; no. 7-8; pp. e333 - e337
• Main Authors: Sekkach, Youssef, Elqatni, Mohamed, Khattabi, Abdessadek El, Fatihi, Jamal, Hammi, Salaheddine, Badaoui, Mohamed, Elomri, Naoual, Mekouar, Fadoua, Amezyane, Taoufik, Abouzahir, Ali, Ghafir, Driss
• Format: Journal Article
• Language: French
• Published: France 01.07.2011
• Subjects: Adolescent; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Humans; Interleukin-6 - antagonists & inhibitors; Male; Remission Induction; Still's Disease, Adult-Onset - drug therapy; Young Adult
• ISSN: 2213-0276
• DOI: 10.1016/j.lpm.2011.03.012

The pathogenesis of Still's disease is best elucidated for the better recognition of the involvement of Many pro-inflammatory cytokines in the genesis of this condition. Publications have reported the contribution beneficial for certain biotherapeutics, such as anti-TNFa, the anti-CD20 or antagonists of interleukine1 (IL-1) tested successfully in the treatment of systemic Juvenile idiopathic arthritis (Still's disease the child), the tocilizumab is a humanized monoclonal antibody directed against the receptor for interleukin-6 and is beginning to be reported as effective in some refractory cases of Still's disease in adults. We report two young patients with Still's disease in adults with refractory early and prolonged remission after the first infusion tocilizumab. The tocilizumab can be used in patients MSA with refractory after failure or intolerance conventional treatments.